Table 2.
Patients´ characteristics of the survival cohort.
| Molecular targeted treatment (n = 19) | Standard treatment (n = 28) | Total (n = 47) | |
|---|---|---|---|
| Median age (range) | 51 (23–73) | 62 (32–82) | 58 (23–82) |
| Sex | |||
| Male | 8 | 15 | 23 |
| Female | 11 | 13 | 24 |
| Tumour type | |||
| iCCA | 18 | 25 | 43 |
| HCC-CCA | 1 | 3 | 4 |
| Systemic treatment lines (median, range) | 4 (2–7) | 2 (1–7) | 3 (1–7) |
| Overall survival (months) (median, range) | 27 (7–100) | 17 (1–111) | 20 (1–111) |
| Number of patients with ≥1 detected genetic alteration | 19 | 24 | 42 |
| Median number of druggable alterations per patient (range) | |||
| iCCA | 1 (1–3) | 1 (0–6) | 1 (0–6) |
| HCC-CCA | 3 | 2 (1–2) | 2 (1–3) |